EU/3/01/024: Orphan designation for the treatment of haemorrhagic fever with renal syndrome

Ribavirin

Table of contents

Overview

Please note that this product was withdrawn from the Community Register of designated Orphan Medicinal Products in February 2009 on request of the sponsor.

On 14 February 2001, orphan designation (EU/3/01/024) was granted by the European Commission to ICN Pharmaceuticals Limited, United Kingdom, for ribavirin for the treatment of haemorrhagic fever with renal syndrome. ICN Pharmaceuticals Limited subsequently changed name to Valeant Pharmaceuticals Ltd.

Key facts

Active substance
Ribavirin
Intended use
Treatment of haemorrhagic fever with renal syndrome
Orphan designation status
Withdrawn
EU designation number
EU/3/01/024
Date of designation
14/02/2001
Sponsor
Valeant Pharmaceuticals Ltd
Cedarwood, Chineham Business Park
Crockford Lane
Basingstoke RG24 8WD
United Kingdom
Telephone: +44 1256 70 77 44
Telefax: +44 1256 70 73 34

Documents related to this orphan designation evaluation

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.

  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.

EU register of orphan medicines

The list of medicines that have received an orphan designation in the EU is available on the European Commission's website:

How useful was this page?

Add your rating